Homocysteinemia, hypertension, and family history of diabetes in a smoking male population in Saudi Arabia
Tóm tắt
Arabs have a lower incidence of atherosclerosis than other ethnicities, but few studies have examined homocysteine (HCYS) as a risk factor for cardiovascular disease in this population. Here, we investigated the association between serum HYCS levels and risk factors for cardiovascular disease (smoking, hypertension, and family history of diabetes) in Saudi males. A total of 50 smokers and 72 nonsmokers completed a general health questionnaire. In addition, their lipid profiles were measured using routine methods and HCYS levels by high-performance liquid chromatograph with electrochemical detection. Regression analysis showed negative associations between HCYS and glucose (r = −0.22; P < 0.05) as well as family history of diabetes (r = −0.21; P < 0.05). HCYS levels were similar between hypertensive and nonhypertensive smokers, but they were significantly elevated in hypertensive nonsmokers (P = 0.027) and lower in smokers with family history of diabetes (P = 0.01). Levels of HCYS among nonsmokers inversely correlated with history of diabetes and elevated glucose. Nonsmokers’ HCYS levels were significantly elevated in the presence of hypertension and correlated with diastolic blood pressure. Thus, HCYS may be a predictor of hypertension among nonsmokers. Until further trials are conducted, we recommend vitamin B6/folic acid supplementation for the Saudi hypertensive population as an adjuvant therapy.
Tài liệu tham khảo
Bleie O., Semb A.G., Grundt H., Nordrehauq J.E., Vollset S.E., Ueland P.M., et al., Homocysteinelowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease, J. Intern. Med., 2007, 262, 244–253
Wierzbicki A.S., Homocysteine and cardiovascular disease: a review of evidence, Diab. Vasc. Dis. Res., 2007, 4, 143–150
Signorello M.G., Viviani G.L., Armani U., Cerone R., Minniti G., Piana A. et al., Homocysteine, reactive oxygen species and nitric oxide in type 2 diabetes mellitus, Thromb. Res., 2007, 120, 607–613
Zakai N.A., Katz R., Jenny N.S., Psaty B.M., Reiner A.P., Schwartz S.M., et al., Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study, J. Thromb. Haemost., 2007, 5, 1125–1127
Gonzales S., Huerta J.M., Fernandez S., Patterson A.M., Laceras C., Homocysteine increases the risk of mortality in elderly individuals, Br. J. Nutr., 2007, 97, 1128–1135
Kennedy B.P., Faraq N.H., Ziegler M.G., Mills P.J., Relationship of systolic blood pressure with plasma homocysteine: importance of smoking status, J. Hypertens., 2003, 21, 1307–1312
Pernod G., Bosson J.L., Golshayan D., Barro C., Alloatti S., Turc-Baron C., et al., Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients, J. Nephrol., 2004, 17, 66–75
Retterstol L., Paus B., Bohn M., Bakken A., Erikssen J., Malinow M.R., Berq K., Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: a 10-year follow-up study, J. Intern. Med., 2003, 253, 284–292
Castelli W.P., Epidemiology of coronary heart disease: the Framingham study, Am. J. Med., 1984, 76, 4–12
Reis R.P., Azinheira J., Reis H.P., Pina J.E., Correia J.M., Luis A.S., Influence of smoking on homocysteinemia at baseline and alter methionine load, Rev. Port. Cardiol., 2000, 19, 471–474
Sharper A.G., Pocock S.J., Walker M., Phillips A.N., Whitehead T.P., MacFarlane T.W., Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study, J. Epidemiol. Community Health, 1985, 39, 197–209
Jarallah J.S., Al-Rubeaan K.A., Al-Nuaim A.R., Al-Ruhaily A.A., Kalantan K.A., Prevalence and determinants of smoking in three regions of Saudi Arabia, Tob. Control., 1999, 8, 53–56
Heidrich J., Wellman J., Heuschmann P.U., Kraywinkel K., Keil U., Mortality and morbidity from coronary heart disease attributable to smoking, Eur. Heart J., 2007, 20, 2498–502
Leone A., Smoking, haemostatic factors and cardiovascular risk, Curr. Pharm. Des., 2007, 13, 1661–1667
O’Callaghan P., Meleady R., Fitzgerald T., Graham I., European COMAC Group, Smoking and plasma homocysteine, Eur. Heart J., 2002, 23, 1580–1586
Al-Nozha M.M., Arafah M.R., Al-Mazrou Y.Y., Al-Maatouq M.A., Khan N.B., Khalil M.Z., et. al., Coronary artery disease in Saudi Arabia. Saudi Med. J., 2004, 25, 1165–1171
Pagan K., Hou J., Goldenberg R.L., Cliver S.P., Tamura T., Effect of smoking on serum concentrations of total homocysteine and B vitamins in mid-pregnancy, Clin. Chim. Acta., 2001, 306, 103–109
Mc Carty M.F., Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute phase induction of pyridoxal phosphatase activity, Med. Hypotheses, 2000, 55, 289–293
Fanapour P.C., Yug B., Kocharn M.S., Hyperhomocysteinemia: an additional cardiovascular risk factor, W.M.J., 1999, 98, 51–54
Giannetti N., Herity N.A., Alimollah A., Gao S.Z., Schroeder J.S., Yeung A.C., et al., Mild Hyperhomocysteinemia is not associated with cardiac allograft coronary disease, Clin. Transplant, 2001, 15, 247–252
Lee B.J., Lin P.T., Liaw Y.P., Chang S.J., Cheng C.H., Huang Y.C., Homocysteine and risk of coronary artery disease: Folate is the important determinant of plasma homocysteine concentration, Nutrition, 2003, 19, 577–583
Gazi I.F., Elisaf M., LDL-cholesterol calculation formulas in patients with or without metabolic syndrome, Int. J. Cardiol., 2007, 119, 414–415
Martin S.C., Tsakas-Ampatzis I., Bartlett W.A., Jones A.F., Measurement of plasma homocysteine by HPLC with coulometric detection, Clin. Chem., 1999, 45, 150–152
Lip G.Y., Edmunds E., Martin S.C., Jones A.F., Blann A.D., Beevers D.G., A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage, Am. J. Hypertens., 2001, 14, 627–631
Tayama J., Munakata M., Yoshinaga K., Toyota T., Higher plasma homocysteine concentration is associated with more advanced systemic arterial stiffness and greater blood pressure response to stress in hypertensive patients, Hypertens. Res., 2006, 29, 403–409
Boers G.H., Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease, Semin. Thromb. Hemost., 2000, 26, 291–295
Rodrigo R., Passalacqua W., Arraya J., Orellana M., Rivera G., Homocysteine and essential hipertensión, J. Clin. Pharmacol., 2003, 43, 1299–1306
Sundstrom J., Sullivan L., D’Agostino R.B., Jacques P.F., Selhub J., Rosenberg R.H. et. al., Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study, Hypertension, 2003, 42, 1100–1105
Stein J.H., Bushara M., Bushara K., McBride P.E., Jorenby D.E., Fiore M.C., Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels, Clin. Cardiol., 2002, 25, 23–26
Tonstad S., Urdal P., Does short-term smoking cessation reduce plasma total homocysteine concentrations? Scand. J. Clin. Lab. Invest, 2002, 62, 279–284
Abu-Amero K.K., Wyngaard C.A., Dzimiri N., Prevalence and role of methylenetetrahydrofolate 677C-T and 1298A-C polymorphism in coronary artery disease in Arabs, Arch. Pathol. Lab. Med., 2003, 127, 1349–1352
Bu R., Gutierrez M.I., Al-Rasheed M., Belgaumi A., Bhatia K., Variable drug metabolism genes in Arab population, Pharmacogenomics, 2004, 4, 260–266
Blum A., Hijazi I., Eizenberg M.M., Blum N., Homocysteine (Hcy) follow-up, Clin. Invest Med., 2007, 30, 21–25
Liao D., Tan H., Hui R., Li Z., Jiang X., Gaubatz J. et al., Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A1 protein synthesis and enhancing HDL cholesterol clearance, Circ. Res., 2006, 99, 565–566
Al-Nozha M., Al-Daghri N., Bartlett W.A., Al-Attas O., Al-Maatouq M., Martin S.C., et al., Serum homocysteine concentration is related to diabetes mellitus, but not to coronary heart disease in Saudi Arabians, Diabetes Obes. Metab., 2002, 4, 118–123